Daiwa Securities recently increased its stake in SELLAS Life Sciences Group as the company nears a crucial Phase 3 REGAL trial readout for acute myeloid leukemia, having completed 78 of the 80 needed events for analysis. This development, coupled with rising institutional ownership and improved cash reserves, suggests a positive shift in SELLAS’s investment narrative, despite persistent execution risks and market volatility. Analysts highlight concerns that current share price expectations may be overly optimistic, with a fair value estimate around $27.50, indicating potential risk if the REGAL trial results fall short.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-group-sls-is-up-137-after-daiwa-boosts
